

**FOR FURTHER INFORMATION CONTACT:**

Gajindar Singh, (202) 564-0634 or [singh.gajindar@epa.gov](mailto:singh.gajindar@epa.gov).

**SUPPLEMENTARY INFORMATION:** The subject memorandum may be viewed and downloaded from EPA's home page, <http://www.epa.gov/owm/mab/104gallocmem05.pdf>.

Dated: July 15, 2005.

**James A. Hanlon,**

*Director, Office of Wastewater Management.*

[FR Doc. 05-14935 Filed 7-27-05; 8:45 am]

**BILLING CODE 6560-50-P**

---

**ENVIRONMENTAL PROTECTION AGENCY**

[FRL-7945-7]

**Approaches for the Application of Physiologically-Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment E-Docket ID No. ORD-2005-0022**

**AGENCY:** Environmental Protection Agency.

**ACTION:** Notice of public comment period.

**SUMMARY:** The U.S. Environmental Protection Agency (EPA) is announcing a 30-day public comment period for the external review draft document titled, "Approaches for the Application of Physiologically-Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment" (EPA/600/R-05/043A). The draft document was prepared by the EPA's National Center for Environmental Assessment (NCEA) within EPA's Office of Research and Development (ORD).

EPA also anticipates that Versar, Inc., an EPA contractor for external scientific peer review, will convene a panel of experts and organize and conduct an external peer-review workshop. This workshop will be announced in a separate **Federal Register** notice, once EPA is notified by Versar, Inc., of the date and location for the workshop. The public comment period and the external peer-review workshop are separate processes that provide opportunities for all interested parties to comment on the document.

**DATES:** The 30-day public comment period begins July 28, 2005, and ends August 29, 2005. Technical comments should be in writing and must be received by EPA by August 29, 2005.

**ADDRESSES:** The draft document and EPA's peer-review charge are available primarily via the Internet on the National Center for Environmental Assessment's home page under the

Recent Additions and Publications menus at <http://www.epa.gov/ncea>. A limited number of paper copies are available from the Technical Information Staff, NCEA-W; telephone: 202-564-3261; facsimile: 202-565-0050. If you are requesting a paper copy, please provide your name, mailing address, and the document title, "Approaches for the Application of Physiologically-Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment" (EPA/600/R-05/043A).

Comments may be submitted electronically via EPA's E-Docket, by mail, by facsimile, or by hand delivery/courier. Please follow the detailed instructions as provided in the **SUPPLEMENTARY INFORMATION** section of this notice.

**FOR FURTHER INFORMATION CONTACT:** For information on the public comment period, contact the OEI Docket; telephone: 202-566-1752; facsimile: 202-566-1753; or e-mail: [ORD.Docket@epa.gov](mailto:ORD.Docket@epa.gov).

If you have questions about the document, please contact the Technical Information Staff, National Center for Environmental Assessment, U.S. Environmental Protection Agency, Washington, DC 20460; telephone: 202-564-3261; facsimile: 202-565-0050; or e-mail: [NCEADC.Comment@epa.gov](mailto:NCEADC.Comment@epa.gov).

**SUPPLEMENTARY INFORMATION:**

**I. Information About the Document**

Physiologically-based pharmacokinetic (PBPK) models represent an important class of dosimetry models that are useful for predicting internal dose at target organs for risk assessment applications. Dose-response relationships that appear unclear or confusing at the administered dose level can become more understandable when expressed on the basis of internal dose of the chemical. To predict internal dose level, PBPK models use pharmacokinetic data to construct mathematical representations of biological processes associated with the absorption, distribution, metabolism, and elimination of compounds. With the appropriate data, these models can be used to extrapolate across species and exposure scenarios, and address various sources of uncertainty in risk assessments. This external review draft document addresses the following questions: (1) Why do risk assessors need PBPK models; (2) How can these models be used in risk assessments; and (3) What are the characteristics of acceptable PBPK models for use in risk assessment?

**II. How To Submit Technical Comments to EPA's E-Docket**

EPA has established an official public docket for information pertaining to "Approaches for the Application of Physiologically-Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment" (EPA/600/R-05/043A), Docket ID No. ORD-2005-0022. The official public docket is the collection of materials available for public viewing and includes the documents specifically referenced in this action, any public comments received, and other information related to this action, but excludes Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. The official public docket is available for public viewing at the Office of Environmental Information (OEI) Docket in the Headquarters EPA Docket Center, (EPA/DC) EPA West Building, Room B102, 1301 Constitution Ave., NW., Washington, DC. The EPA Docket Center Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Public Reading Room is 202-566-1744, and the telephone number for the OEI Docket is 202-566-1752; facsimile: 202-566-1753; or e-mail: [ORD.Docket@epa.gov](mailto:ORD.Docket@epa.gov).

An electronic version of the public docket is available through EPA's electronic public docket and comment system, E-Docket. You may use E-Docket at <http://www.epa.gov/edocket/> to submit or view public comments, to access the index of the contents of the official public docket, and to access those documents in the public docket that are available electronically. Once in the system, select "search," then key in the appropriate docket identification number.

Certain types of information will not be placed in E-Docket. Information claimed as CBI and other information for which disclosure is restricted by statute will not be available for public viewing in the official public docket or in E-Docket. EPA's policy is that copyrighted material will not be placed in EPA's electronic public docket but will be referenced there and will be available as printed material in the official public docket.

If you intend to submit comments to EPA, please note that it is EPA policy to make public comments available for public viewing as received at the EPA Docket Center or in E-Docket. This policy applies to information submitted electronically or in paper form, except where restricted by copyright, CBI, or statute. When EPA identifies a comment

containing copyrighted material, EPA will provide a reference to that material in the version of the comment that is placed in EPA's electronic public docket. The entire printed comment, including the copyrighted material, will be available in the official public docket.

Public comments submitted on computer disks that are mailed or delivered to the EPA Docket Center will be transferred to E-Docket. Public comments that are mailed or delivered to the EPA Docket Center will be scanned and placed in E-Docket. Where practical, physical objects will be photographed, and the photograph will be placed in E-Docket with a brief description written by the docket staff.

You may submit comments electronically, by mail, by facsimile, or by hand delivery/courier. To ensure proper receipt by EPA, include the appropriate docket identification number with your submission. Please ensure that your comments are submitted within the specified comment period. Comments received after the closing date will be marked "late," and may only be considered if time permits.

If you submit comments electronically, EPA recommends that you include your name, mailing address, and an e-mail address or other contact information in the body of your comment. Also include this contact information on the outside of any submitted disk or CD-ROM, and in any cover letter accompanying the disk or CD-ROM. This ensures that you can be identified as the person submitting the comment and allows EPA to contact you in case the Agency cannot read your submission due to technical difficulties or needs further information on the substance of your comment. EPA will not edit your comment, and any identifying or contact information provided in the body of a comment will be included as part of the comment that is placed in the official public docket and made available in E-Docket. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, it may delay or preclude consideration of your comment.

Electronic submission of comments to E-Docket is EPA's preferred method for receiving comments. Go directly to EPA Dockets at <http://www.epa.gov/edocket>, and follow the online instructions for submitting comments. To access EPA's electronic public docket from the EPA Internet Home Page, select "Information Sources," "Dockets," and "EPA Dockets." Once in the system, select "search," and then key in Docket ID No. ORD-2005-0022. The system is an

"anonymous access" system, which means EPA will not know your identity, e-mail address, or other contact information unless you provide it in the body of your comment.

Comments may be sent by electronic mail (e-mail) to [ORD.Docket@epa.gov](mailto:ORD.Docket@epa.gov), Attention Docket ID No. ORD-2005-0022. In contrast to EPA's electronic public docket, EPA's e-mail system is not an "anonymous access" system. If you send an e-mail comment directly to the docket without going through EPA's E-Docket, EPA's e-mail system automatically captures your e-mail address, and it becomes part of the information in the official public docket and in E-Docket.

You may submit comments on a disk or CD-ROM that you mail to the OEI Docket mailing address. Files will be accepted in WordPerfect, Word, or PDF format. Avoid the use of special characters and any form of encryption.

If you provide comments in writing, please submit one unbound original with pages numbered consecutively, and three copies of the comments. For attachments, provide an index, number pages consecutively with the comments, and submit an unbound original and three copies.

Dated: July 22, 2005.

**Peter W. Preuss,**

*Director, National Center for Environmental Assessment.*

[FR Doc. 05-14932 Filed 7-27-05; 8:45 am]

**BILLING CODE 6560-50-P**

---

## FEDERAL ELECTION COMMISSION

### Sunshine Act Notices

**AGENCY:** Federal Election Commission.

**PREVIOUSLY ANNOUNCED DATE AND TIME:** Thursday, July 21, 2005, 10 a.m. Meeting open to the public. This meeting was cancelled.

**PREVIOUSLY ANNOUNCED DATE AND TIME:** Thursday, July 28, 2005, 10 a.m. Meeting open to the public. This meeting was cancelled.

**DATE AND TIME:** Thursday, August 4, 2005, at 10 a.m.

**PLACE:** 999 E Street, NW., Washington, DC (Ninth Floor).

**STATUS:** These hearings will be open to the public.

**MATTERS BEFORE THE COMMISSION:**

(1) State, District, and Local Party Committee Payment of Certain Salaries and Wages;

(2) Definition of Federal Election Activity.

**PERSON TO CONTACT FOR INFORMATION:**

Mr. Robert Biersack, Press Officer, telephone: (202) 694-1220.

**Mary W. Dove,**

*Secretary of the Commission.*

[FR Doc. 05-15068 Filed 7-26-05; 2:30 pm]

**BILLING CODE 6715-01-M**

---

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Program Announcement AA173]

#### **A Cooperative Agreement for the Interstitial Cystitis Association To Develop and Implement a Program To Enhance Interstitial Cystitis Public and Health Provider Awareness Through Partnership, Education and Communication; Notice of Intent To Fund Single Eligibility Award**

##### **A. Purpose**

The Centers for Disease Control and Prevention (CDC) announces the intent to fund fiscal year (FY) 2005 funds for a cooperative agreement program to promote public awareness and partnership, provide interstitial cystitis (IC) education for the general public and for health care providers, and develop and enhance communication channels to allow for improved interaction and information sharing among those with IC, advocates for persons with IC and their families, those who provide care and services for persons with IC, researchers, public health scientists, and the general public. The Catalog of Federal Domestic Assistance number for this program is 93.283.

##### **B. Eligible Applicant**

Assistance will be provided only to Interstitial Cystitis Association, 110 N. Washington Street, Suite 340, Rockville, MD 20850.

Founded in 1984, The Interstitial Cystitis Association (ICA) is a not-for-profit health organization and *the* national leader dedicated to providing patient and physician educational information and programs, patient support, public awareness and, most importantly, research funding for IC. ICA is the *only* not-for-profit national IC organization that promotes and provides funding for much needed IC research. This characteristic of ICA's organization is unmatched by any other public or private IC health organization currently conducting similar activities in the United States. The primary mission of ICA is to research a cure and treatment for IC and provide information and